DHEA-S Level Calculator
Enter your dehydroepiandrosterone sulfate (DHEA-S) blood test result to compare against age and sex-specific reference ranges. This free DHEA-S calculator converts between ug/dL and umol/L units, displays your position on the reference range bar chart, shows the age-decline curve for your sex, and provides clinical interpretation guidance for low, normal, elevated, and tumor-suspicious DHEA-S levels.
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
DHEA-S below the reference range for your age and sex may indicate adrenal insufficiency (Addison disease), hypopituitarism, or medication effects (such as corticosteroids, oral contraceptives, or statins). Further evaluation with morning cortisol, ACTH levels, and potentially ACTH stimulation testing may be recommended by your healthcare provider. Low DHEA-S can also occur with severe systemic illness, chronic stress, and anorexia.
Your DHEA-S is within the expected reference range for your age and sex, suggesting normal adrenal androgen production. This result alone does not exclude all adrenal or hormonal conditions, as DHEA-S is one component of a broader hormonal evaluation. No further adrenal evaluation is typically needed based on a normal DHEA-S result alone, but your healthcare provider may consider other tests depending on your symptoms and clinical context.
DHEA-S above the reference range suggests excess adrenal androgen production. Common causes include polycystic ovary syndrome (PCOS), nonclassic congenital adrenal hyperplasia (21-hydroxylase deficiency), obesity-related adrenal hyperandrogenism, and chronic stress. Further evaluation typically includes total and free testosterone, 17-hydroxyprogesterone, and clinical assessment for signs of hyperandrogenism such as hirsutism, acne, and menstrual irregularity.
DHEA-S above 700 ug/dL (19.0 umol/L) in women is considered tumor-suspicious and should prompt urgent adrenal imaging, typically with CT or MRI. Adrenocortical carcinoma often produces very high DHEA-S levels alongside other adrenal steroids. Not all adrenal tumors produce DHEA-S, and some benign adenomas can cause moderate elevations. Additional workup may include 24-hour urinary free cortisol, midnight salivary cortisol, and dexamethasone suppression testing.
| Age Group | Low (ug/dL) | High (ug/dL) | Low (umol/L) | High (umol/L) |
|---|
| Age Group | Low (ug/dL) | High (ug/dL) | Low (umol/L) | High (umol/L) |
|---|
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
About This DHEA-S Dehydroepiandrosterone Sulfate Level Calculator
This DHEA-S calculator is designed for anyone who has received a dehydroepiandrosterone sulfate blood test result and wants to understand what their level means. Whether you are evaluating adrenal function, investigating causes of hirsutism or acne, monitoring PCOS, assessing adrenarche in children, or simply checking your DHEA-S after a routine blood panel, this tool provides age and sex-specific reference range comparison with automatic unit conversion between ug/dL and umol/L.
The calculator uses established clinical reference ranges compiled from major medical laboratory sources and applies the molecular weight of DHEA-S (368.49 g/mol) for accurate unit conversion. It classifies your result into four categories: below normal, normal, above normal, and markedly elevated (tumor-suspicious), based on the widely accepted reference intervals for your specific age group and biological sex.
The visualization includes two key components: a color-coded reference range bar showing exactly where your value falls within the low, normal, elevated, and critical zones, and an age-decline curve plotting your DHEA-S value against the expected reference band for your sex across the adult lifespan. The expandable clinical interpretation cards provide context-specific guidance about potential causes and recommended next steps for each classification tier.
DHEA-S Level Calculator: Understanding Dehydroepiandrosterone Sulfate Reference Ranges, Clinical Significance, and Adrenal Function Assessment
Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant circulating steroid hormone in the human body and serves as a critical biomarker for adrenal gland function. Produced primarily by the zona reticularis of the adrenal cortex, DHEA-S functions as a precursor hormone that the body converts into more potent androgens such as testosterone and dihydrotestosterone (DHT), as well as estrogens. Unlike its unconjugated form DHEA, which exhibits significant circadian variation and fluctuates throughout the menstrual cycle, DHEA-S maintains relatively stable serum concentrations throughout the day due to its longer half-life of approximately 7 to 10 hours. This stability makes DHEA-S the preferred clinical marker for evaluating adrenal androgen production, diagnosing conditions such as polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), adrenal tumors, and assessing the process of adrenarche in children.
DHEA-S levels follow a distinctive age-related pattern. After a brief postnatal surge, levels decline sharply and remain low throughout early childhood. Around the age of 6 to 8 years, a process called adrenarche triggers a gradual increase in DHEA-S production, with levels rising steadily through puberty and peaking in the second to third decade of life. From approximately age 30 onward, DHEA-S levels decline progressively at a rate of roughly 2% to 5% per year, a phenomenon sometimes referred to as adrenopause. By age 70 to 80, serum DHEA-S levels may be only 10% to 20% of their peak values. This predictable age-related decline, combined with the sex-specific differences in reference ranges (males typically have higher levels than females), makes accurate interpretation of DHEA-S results highly dependent on knowing the patient’s age and sex.
What Is DHEA-S and How Is It Different from DHEA?
Dehydroepiandrosterone (DHEA) and its sulfated conjugate DHEA-S are both C19 steroid hormones produced primarily by the adrenal glands. While they share the same steroid backbone, key differences in their pharmacokinetics and clinical utility distinguish them. DHEA has a relatively short half-life of approximately 15 to 30 minutes and exhibits significant diurnal variation, with levels highest in the morning and lowest in the evening, mirroring the cortisol rhythm driven by adrenocorticotropic hormone (ACTH) pulsatility. DHEA is also influenced by the menstrual cycle, making single-point measurements less reliable for clinical assessment.
DHEA-S, by contrast, is formed through sulfation of DHEA by the enzyme DHEA sulfotransferase (SULT2A1) in the adrenal glands and liver. This sulfoconjugation dramatically extends the half-life to approximately 7 to 10 hours and virtually eliminates circadian variation. The serum concentration of DHEA-S is approximately 300 to 500 times greater than that of DHEA, making it a more robust and reproducible clinical marker. The enzyme steroid sulfatase can convert DHEA-S back to DHEA in peripheral tissues including skin, gonads, and adipose tissue, allowing DHEA-S to function as a circulating reservoir for local androgen and estrogen production through the process of intracrinology.
DHEA-S Reference Ranges by Age and Sex
DHEA-S reference ranges vary substantially by age and sex, and also differ somewhat between laboratories due to assay methodology differences. The values below represent widely accepted clinical reference ranges compiled from major medical laboratory sources. It is important to note that individual laboratories may have slightly different ranges, and clinicians should always interpret results in the context of the specific laboratory’s reference intervals.
For adult females, typical DHEA-S reference ranges by age group are: ages 18 to 29, approximately 45 to 380 ug/dL (1.2 to 10.3 umol/L); ages 30 to 39, approximately 45 to 270 ug/dL (1.2 to 7.3 umol/L); ages 40 to 49, approximately 32 to 240 ug/dL (0.9 to 6.5 umol/L); ages 50 to 59, approximately 26 to 200 ug/dL (0.7 to 5.4 umol/L); ages 60 to 69, approximately 13 to 130 ug/dL (0.4 to 3.5 umol/L); and ages 70 and older, approximately 17 to 90 ug/dL (0.5 to 2.4 umol/L).
For adult males, DHEA-S levels are generally higher: ages 18 to 29, approximately 110 to 510 ug/dL (3.0 to 13.8 umol/L); ages 30 to 39, approximately 110 to 370 ug/dL (3.0 to 10.0 umol/L); ages 40 to 49, approximately 45 to 345 ug/dL (1.2 to 9.4 umol/L); ages 50 to 59, approximately 25 to 240 ug/dL (0.7 to 6.5 umol/L); ages 60 to 69, approximately 20 to 170 ug/dL (0.5 to 4.6 umol/L); and ages 70 and older, approximately 15 to 150 ug/dL (0.4 to 4.1 umol/L).
Reference ranges for DHEA-S can vary between laboratories because different immunoassay platforms and mass spectrometry methods produce slightly different results. Always compare your results to the specific reference range printed on your laboratory report rather than to values found in general reference materials. If monitoring DHEA-S over time, it is advisable to use the same laboratory for consistency.
The Age-Related Decline of DHEA-S: Understanding Adrenopause
DHEA-S levels follow one of the most dramatic age-related endocrine changes observed in human physiology. The pattern begins with elevated levels in the neonatal period, driven by the large fetal adrenal gland. Within weeks after birth, levels decline sharply by 80% or more and remain low throughout early childhood. The onset of adrenarche, typically between ages 6 and 8, marks the beginning of a steady increase in DHEA-S production as the zona reticularis of the adrenal cortex matures and expands.
Peak DHEA-S levels are generally achieved between ages 20 and 30, after which a progressive decline begins. This decline occurs at an estimated rate of 2% to 5% per year, and by the seventh or eighth decade of life, circulating DHEA-S concentrations may be only 10% to 20% of their peak values. This age-associated decline, sometimes called adrenopause, has been the subject of considerable research interest due to its potential associations with aging-related changes including decreased muscle mass, reduced bone density, altered immune function, cognitive decline, and cardiovascular risk.
While the decline itself is a normal physiological process, the rate and degree of decline can vary between individuals. Factors that may influence the rate of DHEA-S decline include genetics, body mass index, chronic illness, medications, and chronic stress. Research from diverse populations worldwide has confirmed this general pattern, though the absolute levels at any given age can vary between ethnic and geographic populations.
Clinical Significance of Elevated DHEA-S Levels
Elevated DHEA-S levels warrant clinical investigation and may indicate several important conditions. In women, the most common cause of moderately elevated DHEA-S is polycystic ovary syndrome (PCOS), where approximately 20% to 30% of affected women demonstrate elevated adrenal androgens alongside elevated ovarian androgens. The elevation in DHEA-S in PCOS is typically mild to moderate and is associated with symptoms including hirsutism, acne, menstrual irregularity, and subfertility.
Congenital adrenal hyperplasia (CAH), particularly the nonclassic (late-onset) form caused by 21-hydroxylase deficiency, is another important cause of elevated DHEA-S. In this condition, enzymatic deficiency in the cortisol synthesis pathway leads to accumulation of upstream precursors including DHEA and DHEA-S. Nonclassic CAH can present similarly to PCOS with hirsutism and menstrual irregularity, making biochemical differentiation important through measurement of 17-hydroxyprogesterone levels.
Adrenal tumors, both benign adenomas and adrenocortical carcinomas, can produce markedly elevated DHEA-S levels. DHEA-S levels exceeding 700 ug/dL (19.0 umol/L) in women are considered highly suggestive of an adrenal tumor and typically warrant urgent imaging evaluation. Adrenocortical carcinoma, though rare, often produces very high DHEA-S levels along with other adrenal androgens and sometimes cortisol. Other causes of elevated DHEA-S include Cushing disease (ACTH-dependent), adrenal hyperplasia, and ectopic ACTH syndrome.
DHEA-S levels exceeding 700 ug/dL (19.0 umol/L) in adult women are considered tumor-suspicious and should prompt urgent adrenal imaging, typically with CT or MRI of the adrenal glands. In men, the clinical significance threshold is less well defined due to naturally higher baseline levels, but markedly elevated values should similarly raise concern for adrenal pathology.
Clinical Significance of Low DHEA-S Levels
Low DHEA-S levels can also have clinical significance, though they must be interpreted carefully in the context of normal age-related decline. Pathologically low levels for age may indicate primary adrenal insufficiency (Addison disease), where destruction of the adrenal cortex leads to reduced production of all adrenal steroids including cortisol, aldosterone, and DHEA-S. In secondary adrenal insufficiency caused by pituitary dysfunction or chronic glucocorticoid therapy, DHEA-S production is similarly reduced due to decreased ACTH stimulation.
Hypopituitarism from any cause, including pituitary adenomas, craniopharyngiomas, traumatic brain injury, or radiation therapy, can result in low DHEA-S through reduced ACTH secretion. Chronic exogenous glucocorticoid use suppresses the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal atrophy and reduced DHEA-S production. This suppression can persist for months after discontinuation of glucocorticoid therapy.
Other conditions associated with low DHEA-S levels include severe systemic illness, anorexia nervosa, chronic stress, and certain medications. Several drug classes can reduce DHEA-S levels, including insulin, oral contraceptives, corticosteroids, certain anticonvulsants (carbamazepine, phenytoin), statins, and dopaminergic agents. When interpreting low DHEA-S results, it is essential to review the patient’s medication list and clinical context.
DHEA-S in the Evaluation of Hirsutism and Virilization
DHEA-S measurement plays a central role in the clinical evaluation of hirsutism and virilization in women. Hirsutism, defined as excessive terminal hair growth in androgen-dependent areas following a male pattern, affects approximately 5% to 10% of women of reproductive age worldwide. The initial biochemical evaluation typically includes total and free testosterone alongside DHEA-S, as this combination allows clinicians to distinguish between ovarian and adrenal sources of excess androgen production.
When DHEA-S is elevated in isolation or disproportionately relative to testosterone, an adrenal source of androgen excess is suggested. This pattern may indicate nonclassic CAH, adrenal adenoma, or adrenocortical carcinoma. When testosterone is elevated with normal DHEA-S, an ovarian source is more likely, suggesting conditions such as PCOS, ovarian hyperthecosis, or rarely, an androgen-secreting ovarian tumor. When both DHEA-S and testosterone are elevated, mixed adrenal and ovarian sources or PCOS with adrenal hyperandrogenism should be considered.
Approximately 84% of women with hirsutism demonstrate elevated androgen levels on biochemical testing. The Ferriman-Gallwey scoring system is commonly used to clinically grade the severity of hirsutism, with scores of 8 or higher (in many populations) considered abnormal. Combining clinical assessment with DHEA-S and other androgen measurements provides the foundation for accurate diagnosis and targeted treatment.
DHEA-S and Adrenarche in Children
In pediatric endocrinology, DHEA-S measurement is valuable for evaluating premature adrenarche and distinguishing it from true central precocious puberty. Adrenarche, the maturation of the adrenal zona reticularis, normally begins between ages 6 and 8 and is characterized biochemically by rising DHEA-S levels. Clinically, adrenarche may manifest as the appearance of pubic hair (pubarche), axillary hair, adult-type body odor, and mild acne.
Premature adrenarche is defined as the appearance of adrenarchal signs before age 8 in girls or age 9 in boys. The key clinical challenge is distinguishing benign premature adrenarche, which is typically a normal variant and does not require treatment, from more serious conditions such as nonclassic CAH, adrenal tumors, or true central precocious puberty. In premature adrenarche, only adrenal androgens (chiefly DHEA-S) are elevated above prepubertal levels, while gonadotropins and gonadal sex steroids remain in the prepubertal range. In true central precocious puberty, gonadotropin levels (LH and FSH) and gonadal steroids are also elevated.
DHEA-S levels above approximately 40 ug/dL (1.1 umol/L) are generally considered consistent with the onset of adrenarche. Research has shown that the timing of adrenarche and the DHEA-S levels at which clinical pubarche appears can vary by sex and population. Longitudinal follow-up of children with premature adrenarche is recommended, as some studies suggest an association with metabolic risk factors and PCOS in later life, though the majority of cases follow a benign course.
DHEA-S and Fertility: Role in Ovarian Reserve Assessment
DHEA-S and its precursor DHEA have attracted significant attention in reproductive medicine, particularly regarding their potential role in improving fertility outcomes in women with diminished ovarian reserve (DOR). DOR is characterized by a decline in the number and quality of remaining oocytes, often assessed through markers such as anti-Mullerian hormone (AMH), antral follicle count (AFC), and day-3 FSH levels. While DHEA-S itself is not a standard marker of ovarian reserve, some research has explored DHEA supplementation as an adjunctive treatment in women undergoing in vitro fertilization (IVF) with diminished ovarian reserve.
The rationale for DHEA supplementation in fertility treatment is that DHEA serves as a substrate for intrafollicular androgen production, which is important for follicular development and oocyte maturation. Some studies have reported improvements in oocyte yield, embryo quality, and pregnancy rates with DHEA supplementation in women with poor ovarian response. However, the evidence remains mixed, and major reproductive medicine societies have not yet endorsed routine DHEA supplementation due to the lack of large, well-designed randomized controlled trials.
When DHEA-S levels are measured in the context of fertility evaluation, extremely low levels for age may suggest overall adrenal androgen insufficiency that could contribute to poor follicular development. However, this remains an area of active research, and clinical decisions about DHEA supplementation should be made in consultation with a reproductive endocrinologist who can consider the individual patient’s complete hormonal profile and clinical situation.
While some evidence suggests potential benefits of DHEA supplementation for fertility in women with diminished ovarian reserve, self-supplementation is not recommended. DHEA supplements are widely available over the counter, but the purity, dosage, and potential side effects (including virilization) necessitate medical supervision. DHEA supplementation can also interfere with interpretation of subsequent DHEA-S blood test results.
Medications and Substances That Affect DHEA-S Levels
Numerous medications and substances can influence DHEA-S levels, and awareness of these interactions is essential for accurate interpretation of test results. Medications that may decrease DHEA-S levels include insulin, oral contraceptives containing estrogen, systemic corticosteroids (including inhaled corticosteroids at high doses), certain anticonvulsants (carbamazepine, clomipramine, imipramine, phenytoin), statins and other antilipemic drugs (cholestyramine), dopaminergic agents (levodopa, bromocriptine), fish oil supplements, and vitamin E.
Medications that may increase DHEA-S levels include metformin, troglitazone, prolactin-elevating medications, many neuroleptic drugs (through indirect mechanisms), danazol, calcium channel blockers (diltiazem, amlodipine), and nicotine. Over-the-counter DHEA supplements, which are classified as dietary supplements rather than prescription drugs in many countries, can substantially elevate DHEA-S levels and may remain elevated for variable periods after discontinuation.
When evaluating DHEA-S results, clinicians should perform a thorough medication review and consider the potential impact of pharmacological agents on the measured values. In general, drug-induced changes in DHEA-S are typically not large enough to cause diagnostic confusion with major pathological conditions, but they can affect interpretation when DHEA-S levels are only mildly abnormal. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before undergoing DHEA-S testing.
DHEA-S Testing: Sample Collection and Assay Methods
DHEA-S testing requires a simple venous blood draw, typically from an antecubital vein. No special preparation is required, and because DHEA-S does not exhibit significant circadian variation, the sample can be drawn at any time of day. This is a significant practical advantage over cortisol or DHEA testing, which require timed sample collection. Patients should inform their healthcare provider about any DHEA-containing supplements, as these can directly affect results.
Modern DHEA-S assays primarily use two methodological approaches: immunoassays and mass spectrometry. Automated immunoassays (chemiluminescent, electrochemiluminescent, or enzyme-linked methods) are the most commonly used in routine clinical laboratories due to their high throughput, rapid turnaround time, and relatively low cost. However, immunoassays can be subject to cross-reactivity with structurally similar steroids and may produce results that differ somewhat between assay platforms from different manufacturers.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the gold standard for steroid hormone measurement and offers superior specificity and sensitivity. LC-MS/MS is particularly valuable when results from immunoassay are discordant with the clinical picture, in pediatric populations where levels may be near or below immunoassay detection limits, and in research settings requiring high accuracy. However, LC-MS/MS is more expensive and has longer turnaround times, limiting its availability in many clinical settings.
DHEA-S in the Context of PCOS Diagnosis
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting an estimated 6% to 12% of women worldwide depending on the diagnostic criteria used. The diagnosis typically relies on the Rotterdam criteria, which require two of three features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. DHEA-S measurement contributes to the assessment of biochemical hyperandrogenism and helps characterize the source of androgen excess.
In PCOS, elevated DHEA-S levels are found in approximately 20% to 30% of cases, reflecting adrenal hyperandrogenism as a component of the disorder. This is important because women with PCOS and adrenal hyperandrogenism may have a somewhat different metabolic and reproductive phenotype compared to those with purely ovarian hyperandrogenism. Some studies suggest that the adrenal phenotype of PCOS may be associated with lower metabolic risk, though this remains debated.
Importantly, DHEA-S testing in the context of suspected PCOS also helps exclude other conditions that mimic PCOS, particularly nonclassic CAH due to 21-hydroxylase deficiency. Both conditions can present with hirsutism, acne, menstrual irregularity, and elevated androgens. When DHEA-S is markedly elevated or when clinical suspicion for CAH is high, an early-morning 17-hydroxyprogesterone level should be obtained, and an ACTH stimulation test may be warranted to definitively exclude nonclassic CAH.
Global Application and Population Considerations
DHEA-S reference ranges established in one population may not be directly applicable to other populations due to differences in genetics, body composition, diet, and environmental factors. Studies conducted across diverse populations in North America, Europe, Asia, Africa, and other regions have generally confirmed the characteristic age-related pattern of DHEA-S levels, but absolute values at any given age can vary between ethnic groups.
Some research suggests that DHEA-S levels may differ between ethnic groups, with some studies reporting lower average levels in certain East Asian populations compared to European or African-descent populations. However, these differences are generally smaller than the variation within any single population, and the clinical significance of modest ethnic differences in DHEA-S levels remains uncertain.
Laboratory assay standardization efforts continue to improve comparability of DHEA-S results across different testing platforms and laboratories. Organizations such as the Centers for Disease Control and Prevention’s Hormone Standardization Program have been working to harmonize steroid hormone measurements, though DHEA-S standardization has received less attention than testosterone and estradiol standardization to date. Clinicians should be aware that reference ranges may need to be adjusted when patients change laboratories or when a laboratory changes its assay platform.
DHEA-S and Aging Research
The dramatic age-related decline in DHEA-S has led to extensive research into whether DHEA-S levels contribute to or merely correlate with aging-related changes. Some observational studies have reported associations between lower DHEA-S levels and increased cardiovascular risk, reduced bone mineral density, decreased cognitive function, depressed mood, and increased mortality, particularly in men. However, observational associations do not establish causation, and confounding factors such as overall health status and chronic disease burden could explain many of these correlations.
Interventional studies of DHEA supplementation in aging adults have produced mixed and largely disappointing results. While some small studies have reported modest improvements in skin quality, bone density, sexual function, and subjective well-being with DHEA supplementation, larger and more rigorous trials have generally failed to demonstrate clinically meaningful benefits for most outcomes. The Endocrine Society’s scientific statement on DHEA therapy notes that the evidence does not support routine use of DHEA supplementation for anti-aging purposes.
Despite the lack of strong evidence for DHEA supplementation as an anti-aging intervention, DHEA-S measurement remains clinically useful as a biomarker. Very low DHEA-S levels for age may prompt investigation for adrenal insufficiency, hypopituitarism, or the effects of medications. Additionally, DHEA-S measurement can be useful in monitoring patients receiving glucocorticoid replacement therapy to assess the adequacy of adrenal androgen replacement.
DHEA-S and Adrenal Insufficiency
DHEA-S is a useful adjunctive marker in the evaluation of adrenal insufficiency, though it is not the primary diagnostic test for this condition. In primary adrenal insufficiency (Addison disease), destruction of the adrenal cortex leads to deficiency of cortisol, aldosterone, and adrenal androgens including DHEA-S. Low DHEA-S levels in the appropriate clinical context can support the diagnosis, particularly when combined with cortisol measurements and ACTH stimulation testing.
In secondary adrenal insufficiency due to pituitary or hypothalamic disease, or from chronic exogenous glucocorticoid use, DHEA-S levels are similarly reduced because ACTH is the primary driver of adrenal DHEA-S production. However, the degree of DHEA-S reduction may be less severe than in primary adrenal insufficiency, and DHEA-S can sometimes remain in the low-normal range even when cortisol production is clearly impaired.
DHEA-S measurement has been proposed as a screening tool for adrenal insufficiency in certain clinical settings, such as evaluating patients on chronic glucocorticoid therapy who may have iatrogenic HPA axis suppression. A very low DHEA-S level in such patients can raise clinical suspicion, though definitive diagnosis requires cortisol measurement and formal ACTH stimulation testing. Some endocrinologists also consider DHEA replacement therapy in patients with adrenal insufficiency who report persistent fatigue, low libido, or reduced quality of life despite adequate cortisol and mineralocorticoid replacement.
Units of Measurement and Conversion for Global Users
DHEA-S results can be reported in several different units depending on the laboratory and geographic region, which can cause confusion when comparing results from different sources. The most commonly used units are micrograms per deciliter (ug/dL), micromoles per liter (umol/L), and micrograms per milliliter (ug/mL). Understanding the relationships between these units is essential for accurate interpretation.
The molecular weight of DHEA-S (as the free acid form of dehydroepiandrosterone 3-sulfate) is 368.49 g/mol. The conversion factor between conventional and SI units is: 1 ug/dL equals 0.02714 umol/L, and conversely, 1 umol/L equals 36.85 ug/dL. For conversion between ug/dL and ug/mL, note that 1 ug/mL equals 100 ug/dL (since 1 mL equals 0.01 dL). Some laboratories may also report results in ng/mL, where 1 ug/dL equals 10 ng/mL.
North American laboratories most commonly report DHEA-S in ug/dL, while laboratories in many other parts of the world use umol/L (SI units). When comparing your results with reference ranges from different sources, always verify that you are using the same units. This calculator provides results and reference ranges in both ug/dL and umol/L to accommodate users from all regions. If your lab report uses a different unit, use the conversion formulas above or consult with your laboratory.
Before entering values into this calculator, verify the units shown on your laboratory report. Common DHEA-S units include ug/dL, umol/L, ug/mL, and ng/mL. Entering a value in the wrong unit will produce an incorrect interpretation. This calculator supports ug/dL and umol/L input with automatic bidirectional conversion.
Interpreting DHEA-S Results: A Clinical Framework
Interpreting DHEA-S results requires integration of the measured value with the patient’s age, sex, clinical presentation, medication history, and results of other relevant laboratory tests. A structured approach to interpretation can help clinicians identify the most likely causes of abnormal values and determine appropriate next steps.
For mildly elevated DHEA-S (above the age-specific reference range but below 700 ug/dL in women), common causes include PCOS, nonclassic CAH, obesity-related adrenal hyperandrogenism, and chronic stress. The next steps typically include measuring total and free testosterone, 17-hydroxyprogesterone (to screen for nonclassic CAH), and conducting clinical evaluation for signs of hyperandrogenism. For moderately elevated DHEA-S (500 to 700 ug/dL in women), more careful evaluation is warranted with consideration of adrenal imaging if clinical suspicion for a tumor is present.
For markedly elevated DHEA-S (above 700 ug/dL in women or markedly above reference range in men), adrenal imaging with CT or MRI should be performed urgently to evaluate for adrenal tumor, particularly adrenocortical carcinoma. Additional evaluation may include 24-hour urinary free cortisol, midnight salivary cortisol, and dexamethasone suppression testing to assess for concurrent cortisol excess. For low DHEA-S levels, evaluation should include morning cortisol measurement, ACTH levels, and potentially ACTH stimulation testing if adrenal insufficiency is suspected.
DHEA-S and Cardiovascular Risk
The relationship between DHEA-S levels and cardiovascular risk has been a subject of considerable epidemiological research, with somewhat different findings in men and women. Several large observational studies have reported that lower DHEA-S levels are associated with increased cardiovascular disease (CVD) risk and mortality in men. The mechanisms underlying this association remain unclear but may involve DHEA-S effects on endothelial function, inflammation, insulin sensitivity, and body composition.
In women, the relationship between DHEA-S and cardiovascular risk is more complex and less consistent. Some studies have found associations between higher DHEA-S levels and reduced cardiovascular risk, while others have reported no significant association or even opposite findings. The relationship may be modified by menopausal status, as DHEA-S becomes a proportionally more important source of sex steroids after menopause.
Despite these observational associations, randomized controlled trials of DHEA supplementation have not demonstrated clear cardiovascular benefits. Current cardiovascular guidelines from major international societies do not recommend DHEA-S measurement as a cardiovascular risk marker or DHEA supplementation for cardiovascular risk reduction. DHEA-S measurement remains primarily indicated for the evaluation of adrenal function and androgen excess rather than cardiovascular risk assessment.
Limitations of DHEA-S Testing
While DHEA-S is a valuable clinical marker, several limitations should be understood for proper interpretation. First, DHEA-S is not a direct measure of androgen activity. DHEA-S itself has very weak androgenic potency, and its clinical significance derives primarily from its conversion to more potent androgens in peripheral tissues. Therefore, a normal DHEA-S level does not exclude significant hyperandrogenism from ovarian or adrenal sources, and an elevated DHEA-S level does not necessarily indicate clinically significant androgen excess.
Second, immunoassay-based DHEA-S measurements can be subject to cross-reactivity with other sulfated steroids, potentially leading to falsely elevated or falsely lowered results. This is particularly relevant when DHEA-S levels are near the boundaries of reference ranges. In cases where immunoassay results are discordant with the clinical picture, confirmation by LC-MS/MS may be warranted.
Third, the wide reference ranges for DHEA-S at any given age mean that a considerable degree of variation is considered normal. A DHEA-S level that is within the reference range may still represent a significant change from an individual’s baseline if serial measurements are available. Conversely, a mildly elevated or mildly low level may simply reflect individual variation rather than pathology. Clinical correlation is always essential, and DHEA-S results should be interpreted as one piece of the diagnostic puzzle rather than in isolation.
Frequently Asked Questions
Conclusion
The DHEA-S level calculator provides a convenient tool for converting between units, comparing your DHEA-S results to age and sex-specific reference ranges, and understanding the clinical significance of your values. DHEA-S is a versatile biomarker with applications ranging from the evaluation of adrenal function and hyperandrogenism to the assessment of adrenarche in children and the monitoring of adrenal insufficiency therapy. Its stability throughout the day, ease of measurement from a simple blood draw, and well-characterized age and sex-specific reference ranges make it one of the most clinically useful adrenal function markers available.
However, DHEA-S results should always be interpreted in the context of a complete clinical evaluation including medical history, physical examination, other laboratory tests, and imaging when indicated. This calculator is designed to provide educational information and general reference ranges, but it cannot replace the clinical judgment of a qualified healthcare professional. If your DHEA-S levels are abnormal or if you have concerns about your adrenal health, hormonal balance, or related symptoms, consult with an endocrinologist or your primary care provider for personalized medical advice and appropriate further evaluation.